Maxim analyst Michael Okunewitch initiated coverage of DMK Pharmaceuticals with a Buy rating and $1.50 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DMK:
- DMK Pharmaceuticals regains full rights for SYMJEPI from USWM
- DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
- DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023
- DMK Pharmaceuticals reports preclinical results on DPI-125
Questions or Comments about the article? Write to editor@tipranks.com